0.4054
price down icon16.93%   -0.0826
 
loading
前日終値:
$0.488
開ける:
$0.4519
24時間の取引高:
430.84K
Relative Volume:
0.57
時価総額:
$17.29M
収益:
$45.91M
当期純損益:
$-4.62M
株価収益率:
-2.8916
EPS:
-0.1402
ネットキャッシュフロー:
$-21.51M
1週間 パフォーマンス:
-47.55%
1か月 パフォーマンス:
-46.90%
6か月 パフォーマンス:
-51.29%
1年 パフォーマンス:
-82.45%
1日の値動き範囲:
Value
$0.3655
$0.4636
1週間の範囲:
Value
$0.3655
$0.83
52週間の値動き範囲:
Value
$0.3655
$2.43

Equillium Inc Stock (EQ) Company Profile

Name
名前
Equillium Inc
Name
セクター
Healthcare (1166)
Name
電話
(858) 412-5302
Name
住所
2223 AVENIDA DE LA PLAYA, LA JOLLA, CA
Name
職員
0
Name
Twitter
Name
次回の収益日
2025-03-26
Name
最新のSEC提出書
Name
EQ's Discussions on Twitter

EQ を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
EQ
Equillium Inc
0.4054 17.29M 45.91M -4.62M -21.51M -0.1402
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.69 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
637.36 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
589.15 35.93B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
268.46 34.75B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
267.39 28.24B 3.81B -644.79M -669.77M -6.24

Equillium Inc Stock (EQ) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2021-10-29 再開されました Stifel Buy
2021-09-15 開始されました Cantor Fitzgerald Overweight
2020-07-14 繰り返されました H.C. Wainwright Buy
2020-07-10 再開されました Stifel Buy
2019-02-22 開始されました SVB Leerink Outperform

Equillium Inc (EQ) 最新ニュース

pulisher
Mar 28, 2025

Leerink Partners Downgrades Equillium (LSE:0A4D) - Nasdaq

Mar 28, 2025
pulisher
Mar 28, 2025

Equillium stock tumbles on Phase 3 study results - Investing.com

Mar 28, 2025
pulisher
Mar 28, 2025

Leerink Partners Downgrades Equillium to Market Perform From Outperform, Adjusts Price Target to $1 From $3 - Marketscreener.com

Mar 28, 2025
pulisher
Mar 28, 2025

Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease - BioSpace

Mar 28, 2025
pulisher
Mar 27, 2025

Equillium Reports 2024 Financials and Clinical Milestones - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium (EQ) Surprises with Smaller Q4 Loss Amid Revenue Dip - GuruFocus.com

Mar 27, 2025
pulisher
Mar 27, 2025

12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium stock hits 52-week low at $0.49 amid market challenges By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium Seeks Accelerated Approval For GVHD Drug Despite Primary Endpoint Miss - Scrip

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium reports mixed results in aGVHD study, seeks FDA fast track By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium pushes for breakthrough status despite missing primary endpoint - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium stock hits 52-week low at $0.49 amid market challenges - Investing.com Australia

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium fails to improve complete response in GVHD treatment study - Seeking Alpha

Mar 27, 2025
pulisher
Mar 27, 2025

Nasdaq Down Over 100 Points; US Initial Jobless Claims Fall - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium drug fails main trial goal but shows longer-term promise - The Pharma Letter

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium, Inc. Announces Results of the Phase 3 Equator Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium reports mixed results in aGVHD study, seeks FDA fast track - Investing.com India

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium Reports Phase 3 Results Of Itolizumab For Acute Graft-Versus-Host Disease - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights - Bluefield Daily Telegraph

Mar 27, 2025
pulisher
Mar 27, 2025

Breakthrough GVHD Treatment: New Drug Extends Response Duration by 4.7x in Phase 3 Trial - StockTitan

Mar 27, 2025
pulisher
Mar 17, 2025

Equillium (EQ) to Release Quarterly Earnings on Monday - Defense World

Mar 17, 2025
pulisher
Mar 07, 2025

Equillium Stock Price, Quotes and Forecasts - Benzinga

Mar 07, 2025
pulisher
Feb 28, 2025

SHAREHOLDER ALERT: Weiss Law Reminds EQ, IMGO, MTCR, and OPNT Shareholders About Its Ongoing Investigations - Marketscreener.com

Feb 28, 2025
pulisher
Feb 28, 2025

Equillium stock rallies 26% on itolizumab study data - MSN

Feb 28, 2025
pulisher
Feb 21, 2025

Here's Why Equillium (EQ) Is a Great 'Buy the Bottom' Stock Now - Zacks Investment Research

Feb 21, 2025
pulisher
Feb 12, 2025

Equillium, Inc.'s (NASDAQ:EQ) Price Is Right But Growth Is Lacking After Shares Rocket 27% - Simply Wall St

Feb 12, 2025
pulisher
Feb 11, 2025

Leerink Partnrs Forecasts Stronger Earnings for Equillium - Defense World

Feb 11, 2025
pulisher
Feb 10, 2025

Equillium (EQ) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Feb 10, 2025
pulisher
Feb 10, 2025

Equillium (EQ) Shows Fast-paced Momentum But Is Still a Bargain Stock - Nasdaq

Feb 10, 2025
pulisher
Feb 10, 2025

Healthy Upside Potential: Equillium Inc (EQ) - SETE News

Feb 10, 2025
pulisher
Feb 10, 2025

Equillium Inc (EQ) Stock: Uncovering 52-Week Market Trends - The InvestChronicle

Feb 10, 2025
pulisher
Feb 10, 2025

Equillium reports positive Phase 2 ulcerative colitis study data - MSN

Feb 10, 2025
pulisher
Feb 07, 2025

why Borr Drilling Ltd [BORR] is a Good Choice for Investors After New Price Target of $5.23 - The DBT News

Feb 07, 2025
pulisher
Feb 07, 2025

Callan JMB Inc [CJMB] gain 54.15% so far this year. What now? - The DBT News

Feb 07, 2025
pulisher
Feb 07, 2025

Wall Street Analyst Resumed Equillium Inc [EQ]. What else is Wall St. saying - The DBT News

Feb 07, 2025
pulisher
Feb 07, 2025

Equillium Inc [EQ] Shares Rise 33.03 % on Thursday - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

What to expect from Equillium Inc’s (EQ) current quarter earnings? - US Post News

Feb 07, 2025
pulisher
Feb 07, 2025

Insider Selling: Nachiappan Venkatachalam, Arhaus Inc [ARHS] Chief Information Officer divested 6,460 shares - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

10% Owner HGC Next Inv LLC acquire 11,690,909 shares of NextDecade Corporation [NEXT] - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

CuriosityStream And 2 Other Promising Penny Stocks On US Exchange - Simply Wall St

Feb 07, 2025
pulisher
Feb 07, 2025

Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis - StreetInsider.com

Feb 07, 2025
pulisher
Feb 07, 2025

Equillium and Biocon announce positive data from Phase 2 study evaluating Itolizumab for ulcerative colitis - Indian Pharma Post

Feb 07, 2025
pulisher
Feb 07, 2025

UDR Inc (UDR) Q4 2024 Earnings Call Highlights: Strong Occupancy and Strategic Growth Plans ... - Yahoo Finance UK

Feb 07, 2025
pulisher
Feb 07, 2025

Biocon, Equillium announce positive data from Phase 2 Study evaluating Itolizumab for Ulcerative Colitis - Medical Dialogues

Feb 07, 2025
pulisher
Feb 06, 2025

Stocks to Watch, Feb 7: Biocon, SBI, LIC, M&M, Bharti Airtel, Ola Electric - Business Standard

Feb 06, 2025
pulisher
Feb 06, 2025

Equillium Reports Positive Phase 2 Results for Itolizumab in Ulcerative Colitis, Shares Surge - Yahoo Finance

Feb 06, 2025
pulisher
Feb 06, 2025

Equillium reports positive Phase 2 ulcerative colitis study data By Investing.com - Investing.com South Africa

Feb 06, 2025
pulisher
Feb 06, 2025

Equillium Announces Positive Data from Phase 2 Study Evaluating - GuruFocus.com

Feb 06, 2025
pulisher
Feb 06, 2025

Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis – Company AnnouncementFT.com - Financial Times

Feb 06, 2025
pulisher
Feb 04, 2025

Lugman Group withdraws from purchase of “Industrial Park Fechenheim” - Yahoo Finance UK

Feb 04, 2025

Equillium Inc (EQ) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Equillium Inc (EQ) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Keyes Jason A
Chief Financial Officer
Nov 14 '24
Sale
0.70
10,000
7,000
47,720
$77.99
price up icon 0.39%
$306.97
price down icon 0.34%
$31.37
price down icon 0.88%
$20.32
price down icon 1.36%
$94.95
price down icon 0.47%
biotechnology ONC
$267.39
price up icon 1.82%
大文字化:     |  ボリューム (24 時間):